Primmune Therapeutics
PrivateLast Round
Series B
Extension
Jan 26, 2026
Total Funding Raised
$47M
Company Overview
Primmune Therapeutics is a biopharmaceutical company that develops an orally administered toll-like receptor agonist aimed at enhancing innate immunity for cancer immunotherapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Defense Tech
Business Model
B2G
Customer Profile
Government Contracts, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Primmune Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Primmune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Jan 26, 2026 | ||||
| Grant | Mar 20, 2024 | ||||
| Series A | Jan 12, 2021 | ||||
| Seed | Mar 2, 2020 |
Key People
Founding team and executive leadership
Primmune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CAM Capital | Series A, Seed |
| BioRock Ventures | Series A, Seed |
| Bioqube Ventures | Series B Extension, Series A |
| Oberland Capital Management | Series B Extension |
| BioBrit | Series A, Seed |
| Polaris Partners | Series A |
| Samsara BioCapital | Series B Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 5, 2026
Chris Krueger appointed as Executive Chairman of the Board.
- Feb 5, 2026
Andrew Sharabi, M.D., Ph.D. appointed as new CMO.
Primmune Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Primmune Therapeutics's valuation, stock price, and market status.
